Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review

Links shared publicly online about this topic.

907
total visits

Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review

Iluvien(R) (fluocinolone acetonide intravitreal insert), an investigational sustained drug delivery system that releases sub-microgram levels of fluocinolone acetonide for DME (diabetic macular e

View full resource at medicalnewstoday.com

Tags: Edema, Diabetes, Drug, FDA

Most Recently Shared on August 31, 2010 at 8:00 pm By:

MNT Drug Approvals

Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review http://mnt.to/3J6s #regulatory

2 years ago...

Retweet

Favorite

Also Shared By:

Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com

keyvive.com — “Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com

Most Recently Shared on September 1, 2010 at 2:10 pm By:

Aimee Greenholtz ePatient

Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review: Iluvien(R) (fluocinoloneâ€¦ http://goo.gl/fb/bDodP

2 years ago...

Retweet

Favorite

pSivida announces FDA Priority Review status for Iluvien NDA

news-medical.net — “pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).” View full resource at news-medical.net